Friday, April 28, 2023, San Antonio, Texas, 6:00 AM – 7:30 AM Central Time (7:00 AM – 8:30 AM Eastern Time)

What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial Participation

Fifteenth Annual RTP Symposium Series Held During the Annual ONS Congress

Hepatobiliary Cancers

 
Location
Grand Hyatt San Antonio River Walk
600 E Market Street
San Antonio, TX 78205
Hotel Phone: (210) 224-1234

Program Schedule — Central Time
5:30 AM – 6:00 AM — Registration
6:00 AM – 7:30 AM — Breakfast Meeting

Meeting Room
Texas Ballroom (Salons A-C) – Fourth Floor


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.  
 
Faculty
Ahmed Omar Kaseb, MD, CMQ
John E and Dorothy J Harris Professor
in Gastrointestinal Cancer Research
Member, National Hepatobiliary Task Force
NCI, USA
Tenured Professor and Director, Hepatocellular Carcinoma Program
Director, MD Anderson HCC SPORE
Editor-in-Chief
Journal of Hepatocellular Carcinoma
Department of Gastrointestinal Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Blanca Ledezma, MSN, NP, AOCNP
Nurse Practitioner III
UCLA Santa Monica Hematology/Oncology
UCLA Health
Santa Monica, California


Daneng Li, MD
Associate Professor
Department of Medical Oncology
and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

Amanda K Wagner, APRN-CNP, AOCNP
GI Malignancies
The James Cancer Hospital
The Ohio State University
Columbus, Ohio

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP, Eisai Inc, Incyte Corporation, Merck, and Taiho Oncology Inc during the Oncology Nursing Society’s (ONS) 48th Annual Congress, April 26–30, 2023 in San Antonio, Texas. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement.
Program Schedule — Central Time
5:30 AM – 6:00 AM — Registration
6:00 AM – 7:30 AM — Educational Breakfast Meeting

What I Tell My Patients About ...

First-Line Therapy with Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma (HCC)

  • Impact of clinical and biologic factors on the selection of first-line treatment for patients with advanced HCC
  • Biologic rationale for combining anti-PD-1/PD-L1 and anti-VEGF antibodies for advanced HCC
  • Selection of patients appropriate for up-front treatment with atezolizumab/bevacizumab
  • Role of atezolizumab/bevacizumab for patients who would not have qualified for participation in the pivotal trial, such as those with Child-Pugh B disease

Up-Front Treatment with Dual Immune Checkpoint Inhibitor Therapy for HCC

  • Scientific justification for the use of anti-PD-1/PD-L1 antibodies in combination with anti-CTLA-4 antibodies as first-line treatment for HCC
  • Published findings with durvalumab and tremelimumab as first-line treatment for advanced HCC
  • Recent FDA approval of durvalumab/tremelimumab for unresectable HCC; advantages and disadvantages compared to other evidence-based front-line options
  • Selection of appropriate candidates for up-front durvalumab/tremelimumab

The Role of Tyrosine Kinase Inhibitor (TKI) Monotherapy for Newly Diagnosed Advanced HCC

  • Clinical trial database supporting the use of sorafenib and lenvatinib as first-line therapy for unresectable HCC
  • Recently presented findings demonstrating a potential advantage for lenvatinib over immunotherapeutic approaches in nonviral disease
  • Selection of patients appropriate for up-front treatment with TKI monotherapy

Selection and Sequencing of Therapy for Relapsed/Refractory (R/R) HCC

  • Role of approved first-line TKIs, such as sorafenib and lenvatinib, among patients with R/R HCC
  • Long-term outcomes with approved anti-angiogenic agents (eg, regorafenib, cabozantinib, ramucirumab) among patients with progressive disease
  • Pivotal studies defining the utility of anti-PD-1/PD-L1 antibodies for patients with R/R HCC

Toxicities and Other Practical Considerations with Immune Checkpoint Inhibitor-Based Regimens for HCC

  • Pathophysiology of immune-related adverse events (irAEs); spectrum, incidence and severity of irAEs and other toxicities observed with anti-PD-1/PD-L1 antibodies for HCC
  • Impact on the tolerability of anti-PD-1/PD-L1 antibodies when administered in combination with other systemic therapies, such as anti-angiogenic agents or anti-CTLA-4 antibodies
  • Recommended algorithms for monitoring and managing immune-related and other adverse events with immune checkpoint inhibitors for HCC
  • Relative and absolute contraindications to immune checkpoint inhibitors; role in therapy for patients with HCC and active hepatitis B or C infection, preexisting autoimmune complications or a history of solid organ transplant

The Tolerability of Anti-angiogenic Agents Used in the Treatment of HCC

  • Spectrum of class-effect adverse events, including fatigue, dermatologic toxicities, hypertension and gastrointestinal symptoms, associated with multikinase inhibitors
  • Comparative frequency and severity of common and unique side effects with sorafenib, lenvatinib, cabozantinib, regorafenib and ramucirumab for HCC; implications for treatment selection
  • Approaches to monitoring for and managing toxicities associated with commonly employed anti-angiogenic agents for HCC

The Role of Immunotherapy in the Treatment of Biliary Tract Cancers

  • Key findings with durvalumab in combination with chemotherapy as first-line treatment for patients with advanced biliary tract cancers
  • Tolerability of durvalumab in combination with chemotherapy for biliary tract cancers
  • Recent FDA approval and current clinical role of durvalumab/chemotherapy as first-line treatment for advanced biliary tract cancers
  • Emerging results with pembrolizumab combined with cisplatin/gemcitabine as first-line therapy for advanced biliary tract cancers

The Importance of Biomarker Testing for Patients with Advanced Biliary Tract Cancers

  • Spectrum and clinical relevance of genomic aberrations in patients with advanced biliary tract cancers
  • Comparative prevalence of genetic mutations or alterations in various biliary tract cancers, such as intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma or gallbladder cancer
  • Available platforms for and optimal timing of genomic evaluation

The Role of FGFR Inhibitors in the Management of Advanced Cholangiocarcinoma

  • Pharmacologic and pharmacodynamic similarities and differences between pemigatinib and futibatinib
  • Principal findings supporting the FDA approvals of pemigatinib and futibatinib for patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement
  • Optimal selection and sequencing of FGFR inhibitors for eligible patients with cholangiocarcinoma
  • Ongoing Phase III trials evaluating FGFR inhibition for patients with treatment-naïve cholangiocarcinoma

Tolerability and Other Considerations with FGFR Inhibitors for Cholangiocarcinoma

  • Comparative tolerability profiles of the approved FGFR inhibitors for cholangiocarcinoma; implications for therapeutic selection
  • Pathophysiology of the ocular toxicities observed with pemigatinib and futibatinib; appropriate monitoring and management protocols
  • Incidence and management of other common adverse events reported with pemigatinib and futibatinib (hyperphosphatemia, nail changes, stomatitis, hand-foot syndrome, dry skin, et cetera)
  • Role, if any, for rechallenge with an FGFR inhibitor for patients who have experienced disease progression on prior FGFR inhibitor therapy

The Role of Ivosidenib in Therapy for Advanced Cholangiocarcinoma

  • Published findings with ivosidenib for patients with previously treated cholangiocarcinoma and an IDH1 mutation
  • FDA approval of ivosidenib for IDH1-mutant cholangiocarcinoma; selection of patients appropriate for this strategy
  • Spectrum and frequency of commonly occurring toxicities reported with ivosidenib for cholangiocarcinoma

Other Promising Targeted Therapies for Advanced Biliary Tract Cancers

  • Educating patients regarding the potential advantages of participating in a clinical research study
  • Efficacy and safety observed with trastuzumab deruxtecan in HER2-positive and HER2-low biliary tract cancers; potential role in practice
  • Other promising biomarker-based strategies for patients with advanced biliary tract cancers

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of hepatobiliary cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider the importance of age, performance status and other clinical factors in the selection of up-front therapy for patients with unresectable or metastatic hepatocellular carcinoma (HCC) in order to counsel them about personalized treatment recommendations.
  • Appreciate Phase III data with novel first-line combination strategies for unresectable or metastatic HCC, and discuss how these regimens may be optimally integrated into patient care.
  • Communicate the benefits and risks of approved systemic treatments to patients with progressive HCC to facilitate shared decision-making.
  • Evaluate available and emerging data documenting the efficacy of anti-PD-1/PD-L1 antibody therapy in combination with chemotherapy as first-line treatment for advanced biliary tract cancers, and consider the role of this strategy in practice.
  • Assess key data sets supporting the FDA approvals of fibroblast growth factor receptor (FGFR) inhibitors for previously treated unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement, and consider how these agents can be appropriately and safely integrated into clinical management algorithms.
  • Recall available and emerging data with investigational agents and strategies for HCC and biliary tract cancers, and refer eligible patients for trial participation.

Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. https://www.researchtopractice.com/Meetings/ONS2023/Hepatobiliary/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs Wagner has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr KasebAdvisory Committee, Consulting Agreements and Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Merck. Ms LedezmaSpeakers Bureau: Amgen Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Lilly. Dr LiConsulting Agreements: Coherus BioSciences, Delcath Systems Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Ipsen Biopharmaceuticals Inc, Merck, Servier Pharmaceuticals LLC, TerSera Therapeutics LLC; Contracted Research: AstraZeneca Pharmaceuticals LP, Brooklyn ImmunoTherapeutics.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Eisai Inc, Incyte Corporation, Merck, and Taiho Oncology Inc.

Grand Hyatt San Antonio River Walk
600 E Market Street
San Antonio, TX 78205
Hotel Phone: (210) 224-1234

Meeting Room:
Texas Ballroom (Salons A-C) – Fourth Floor

The Grand Hyatt San Antonio is the headquarters hotel for the 2023 ONS Congress and is conveniently connected to the Henry B González Convention Center.

 

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of hepatobiliary cancers.

​ ​
IN-PERSON registration
Thank you for your interest in our NCPD program taking place in San Antonio, Texas. At this time online preregistration for in-person is closed for this event. LIMITED SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 5:30 AM Central Time on Friday, April 28th. If you are interested in attending, please visit our registration desk located outside the Texas Ballroom (Salons A-C) – Fourth Floor of the Grand Hyatt San Antonio River Walk hotel which is connected to the Henry B Gonzalez Convention Center.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com.

Please note, onsite registration does not guarantee seating and participation in meal service and will be based on availability.

LIVE WEBCAST registration open to all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.